Fatal pulmonary toxicity resulting from treatment with gemcitabine
Authors:
- David R. BellDBDavid R. Bell
Open Access
Abstract
BACKGROUND Pulmonary toxicity reported with gemcitabine is usually mild and self‐limiting. The authors report a series of three patients who had life‐threatening pulmonary toxicity after receiving gemcitabine. METHODS The three patients presented to two major teaching hospitals with significant pulmonary dysfunction while receiving gemcitabine. Case data were obtained from patient records. A review of the literature was done to seek reports of pulmonary toxicity with gemcitabine and cytosine arabinoside (ara‐C). RESULTS The common features of the respiratory illnesses of the three patients in this study were tachypnea, marked hypoxemia, and an interstitial infiltrate on chest radiograph consistent with pulmonary edema. There was no evidence of underlying heart disease in any patient. In addition, there was no evidence of infection, metabolic causes, or lymphangitic carcinomatosis to explain the clinical findings. Two patients died, and postmortem examination confirmed acute RDS (respiratory distress syndrome), whereas in the third patient a transbronchial biopsy showed interstitial pneumonitis. These findings were consistent with drug‐induced pulmonary toxicity. Diuretics and corticosteroids were useful measures for treating the patients' symptoms, and one patient survived after gemcitabine was withdrawn. CONCLUSIONS These three cases of acute RDS may be the result of a capillary leak phenomenon due to treatment with gemcitabine, as observed in patients given intermediate dose and high dose ara‐C, a drug similar in structure and metabolism to gemcitabine. The authors suggest caution in repeated administration of gemcitabine to patients who develop unexplained noncardiogenic pulmonary edema. Withdrawing gemcitabine and administering corticosteroids and diuretics may help to avert a fatal outcome. Cancer 1997; 80:286‐91. © 1997 American Cancer Society.Keywords
This publication has 19 references indexed in Scilit:
- A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerAnnals of Oncology, 1996
- Radiosensitization of pancreatic cancer cells by 2′,2′-difluoro-2′-deoxycytidineInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1996
- 950 Dyspnoea with gemcitabine is commonly seen, often disease related, transient, and rarely severeEuropean Journal of Cancer, 1995
- Injury to the lung from cancer therapy: Clinical syndromes, measurable endpoints, and potential scoring systemsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- The Acute Respiratory Distress SyndromeNew England Journal of Medicine, 1995
- Phase II Study of Gemcitabine (2',2'-Difluorodeoxycytidine) in Previously Treated Ovarian Cancer PatientsJNCI: Journal of the National Cancer Institute, 1994
- Pulmonary complications of cytosine-arabinoside therapy: radiographic findingsAmerican Journal of Roentgenology, 1987
- Subacute pulmonary failure complicating therapy with high-dose ara-C in acute leukemiaCancer, 1985
- Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemiaThe American Journal of Medicine, 1981
- Bilateral radiation pneumonitis, a complication of the radiotherapy of bronchogenic carcinoma (report and analysis of seven cases with autopsy)Cancer, 1969